Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
06 Juin 2023 - 10:01PM
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that
management will participate in a fireside chat at the Goldman Sachs
44th Annual Global Healthcare Conference on Tuesday, June 13, 2023
at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time).
A live webcast of Kiniksa’s presentation will be accessible
through the Investors & Media section of the company’s website
at www.kiniksa.com. A replay of the event will also be available on
Kiniksa’s website within approximately 48 hours after the
event.
About KiniksaKiniksa is a biopharmaceutical
company focused on discovering, acquiring, developing, and
commercializing therapeutic medicines for patients suffering from
debilitating diseases with significant unmet medical need.
Kiniksa’s immune-modulating assets, ARCALYST, KPL-404, and
mavrilimumab, are based on strong biologic rationale or validated
mechanisms, target a spectrum of underserved cardiovascular and
autoimmune conditions, and offer the potential for differentiation.
For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
Every Second
Counts! ®Kiniksa Investor and
Media ContactRachel Frank(339)
970-9437rfrank@kiniksa.com |
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024